Fine analysis of atypical circulating tumor cells in metastatic breast cancer patients reveals subsets with different prognostic values

Purpose: Circulating tumor cells (CTCs) have a tremendous potential for diagnosis and treatment of breast cancer patients. Here, we performed a unique analysis of all atypical circulating cells isolated with a filtration-based technology from metastatic breast cancer (mBC) patients. Patients and methods: The PERMED-01 study enrolled patients with mBC, refractory to systemic therapy, and with an accessible lesion to biopsy. We analyzed atypical circulating cells isolated from patients' blood at the time of inclusion using Screencell(R) Cyto device. For 23 out of 91 analyzed patients, this was completed by advanced immunofluorescence staining of atypical circulating cells. Subsets cut-offs were established using a two-component Gaussian finite Mixture Model, and evaluated for correlation with clinico-pathological data, including progression-free survival (PFS) and overall survival (OS). Results: Three subsets of atypical circulating cells, absent from controls (n=7), were observed in cancer patients (n=91): isolated (iCTCs), Clusters (CTM), and Giant CTCs (gCTCs). CTCs' median number was 8.33 per mL. Co-expression of stem and drug resistance markers was associated with intermediate epithelial to mesenchymal transition phenotype in CTM and gCTCs, but not in iCTCs. Presence of gCTC was associated with shorter PFS and OS. Concerning PFS, assigning an immunofluorescence-based Epithelial to Mesenchymal status improved their prognostic value. Conclusion: This study brings to light the diversity of CTCs in mBC patients and their specific molecular profiles regarding epithelial to mesenchymal transition, stemness and drug resistance status. It also highlights the involvement of an atypical circulating cell subset, the gCTCs, as a prognostic factor for PFS and OS.

[1]  T. Fehm,et al.  Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. , 2014, The Lancet. Oncology.

[2]  W. Catalona,et al.  Circulating giant macrophages as a potential biomarker of solid tumors , 2014, Proceedings of the National Academy of Sciences.

[3]  M. Mascalchi,et al.  Prevalence and number of circulating tumour cells and microemboli at diagnosis of advanced NSCLC , 2015, Journal of Cancer Research and Clinical Oncology.

[4]  Crispin J. Miller,et al.  Vasculogenic mimicry in small cell lung cancer , 2016, Nature Communications.

[5]  Caroline Dive,et al.  Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  Cyrus M. Ghajar,et al.  Circulating and disseminated tumor cells: harbingers or initiators of metastasis? , 2017, Molecular oncology.

[7]  Sridhar Ramaswamy,et al.  A microfluidic device for label-free, physical capture of circulating tumor cell-clusters , 2015, Nature Methods.

[8]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[9]  A. Schneeweiss,et al.  Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer , 2018, Breast Cancer Research and Treatment.

[10]  D G Altman,et al.  REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British journal of cancer.

[11]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Z. Werb,et al.  Circulating Tumor Cells , 2013, Science.

[13]  D. Irwin,et al.  Tumacrophage: macrophages transformed into tumor stem-like cells by virulent genetic material from tumor cells. , 2017, Oncotarget.

[14]  Shinji Iizuka,et al.  Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival , 2018, Science Advances.

[15]  P. Bendahl,et al.  Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort , 2016, BMC Cancer.

[16]  Hushan Yang,et al.  Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer , 2016, International journal of molecular sciences.

[17]  K. Pantel,et al.  Expression of Epithelial Mesenchymal Transition and Cancer Stem Cell Markers in Circulating Tumor Cells. , 2017, Advances in experimental medicine and biology.

[18]  S. Mai,et al.  Filtration-based enrichment of circulating tumor cells from all prostate cancer risk groups. , 2017, Urologic oncology.

[19]  S. Capitani,et al.  CD133 in Breast Cancer Cells: More than a Stem Cell Marker , 2019, Journal of oncology.

[20]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[21]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[22]  Hailin Tang,et al.  LGR5 Promotes Breast Cancer Progression and Maintains Stem‐Like Cells Through Activation of Wnt/β‐Catenin Signaling , 2015, Stem cells.

[23]  Alison Stopeck,et al.  Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  K. Lillemoe,et al.  Cytologic characteristics of circulating epithelioid cells in pancreatic disease , 2017, Cancer cytopathology.

[25]  N. Loman,et al.  Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial , 2018, Breast Cancer Research.

[26]  M. Duma.  [Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer]. , 2018, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[27]  Devanand M. Pinto,et al.  Comparative performance of different methods for circulating tumor cell enrichment in metastatic breast cancer patients , 2020, PloS one.

[28]  F. Bidard,et al.  Circulating Tumor Cells in Early Breast Cancer , 2019, JNCI cancer spectrum.

[29]  K. Scotlandi,et al.  The ABC subfamily A transporters: multifaceted players with incipient potentialities in cancer. , 2020, Seminars in cancer biology.

[30]  R. Piñeiro,et al.  Analysis of a Real-World Cohort of Metastatic Breast Cancer Patients Shows Circulating Tumor Cell Clusters (CTC-clusters) as Predictors of Patient Outcomes , 2020, Cancers.

[31]  F. Francescangeli,et al.  Breast Cancer Stem Cells as Drivers of Tumor Chemoresistance, Dormancy and Relapse: New Challenges and Therapeutic Opportunities , 2019, Cancers.

[32]  P. Jänne,et al.  A new device for rapid isolation by size and characterization of rare circulating tumor cells. , 2011, Anticancer research.

[33]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[34]  G. Hortobagyi,et al.  Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study , 2019, Clinical Cancer Research.

[35]  V. LeBleu,et al.  EMT Program is Dispensable for Metastasis but Induces Chemoresistance in Pancreatic Cancer , 2015, Nature.

[36]  Hushan Yang,et al.  Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer , 2016, Breast Cancer Research and Treatment.

[37]  You-hong Cui,et al.  Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis , 2017, Scientific Reports.

[38]  Joshua M. Kunken,et al.  Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers , 2012, Physical biology.

[39]  Sridhar Ramaswamy,et al.  Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis , 2014, Cell.

[40]  S. Ceccarelli,et al.  EpCAM-Expressing Circulating Tumor Cells in Colorectal Cancer , 2017, The International journal of biological markers.

[41]  T. Fehm,et al.  The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. , 2019, Critical reviews in oncology/hematology.

[42]  Mehmet Toner,et al.  Clusters of circulating tumor cells traverse capillary-sized vessels , 2016, Proceedings of the National Academy of Sciences.

[43]  M. Cristofanilli,et al.  Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer , 2018, JAMA oncology.

[44]  D. Irwin,et al.  Tumacrophage: macrophages transformed into tumor stem-like cells by virulent genetic material from tumor cells , 2017, Oncotarget.